PainChek reports material sales momentum in UK
Filed with ASX · · 2 pages · English
Summary by 6ix AI
PainChek Ltd reports significant sales growth in the UK aged care market, highlighting the addition of new contracted licenses and increased annual recurring revenue. The company emphasizes the growing demand for its AI-powered pain assessment technology, which is recognized as a priority solution in aged care settings. PainChek is also making progress in North America and developing its Infants product, with plans for future updates on these initiatives.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from PainChek
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- PainChek Business Update
- PainChek gains access to RTM reimbursement in USA
- AGM Presentation
Later from PainChek
- Landmark Sabra North America deployment targeting 20k beds
- PainChek secures A$5.5m note to fund US expansion
- CEO Transition
- US MedTech leader Karen Holzberger appointed CEO
- PainChek receives $1.123 million R&D tax incentive refund
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek